Unintended Consequences: Biosimilar Reimbursement Policies and Their Impact on Sustainability
Monday, October 27, 2025
10:45 a.m. - 12:00 p.m.
As biosimilars play a growing role in improving patient access to affordable care, reimbursement policies, especially Medicare’s reimbursement policies, have not evolved to support a financially viable ecosystem for manufacturers and providers. This session explores how current reimbursement frameworks—though designed to reduce costs—may inadvertently undermine long-term market sustainability. By examining the average sales price (ASP) data for the last 10 years of biosimilars, we’ll highlight overall trends related to competition, time on the market, and other factors; discuss key factors related to provider adoption and manufacturer viability; and identify areas where policy reform is urgently needed. Participants will gain insight into the hidden dynamics of biosimilar competition and reimbursement and solutions that can reconcile cost-savings with durable access.
Participants:
Dinakaran Balasubramanian
Head of Commercial Strategy, Dr. Reddy’s Laboratories, Inc.
Conrad Bhamani
Manager, IQVIA Institute for Human Data Sciences
Madelaine Feldman, M.D., FACR
Vice President, Advocacy & Government Affairs, Coalition of State Rheumatology Organizations
Moderator: Shana Christrup
Senior Director, Policy, AAM
